BNTX - Arcturus gains after announcing early data from COVID-19 booster study

Arcturus Therapeutics (ARCT +13.3%) has added more than a tenth in value to record its sharpest intraday gain in four months after announcing preliminary data from its ongoing booster studies for messenger-RNA-based COVID-19 vaccine candidates, ARCT-154 and ARCT-165. In the booster cohort of the Phase 1/2 study, currently, in progress in the U.S. and Singapore, 24 participants across two equal groups received five micrograms of ARCT-154 or ARCT-165. Five months ago, they all had received the initial vaccinations with the Comirnaty vaccine from Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX). In those who received ARCT-154 booster, the neutralizing antibody levels against SARS-CoV-2 increased by 50-fold, the company said, citing a pseudovirus microneutralization (MNT) assay. With plans for studies on the sera of the participants who received ARCT-154 and ARCT-165 for activity against Omicron variant, Arcturus (NASDAQ:ARCT) plans to share initial data in Q1 2022.

For further details see:

Arcturus gains after announcing early data from COVID-19 booster study